Nearly 1 in 5 U.S. Adults Try GLP-1 Shots as At-Home Injectables Spread
Updated
Updated · The New York Times · Aug 17
Nearly 1 in 5 U.S. Adults Try GLP-1 Shots as At-Home Injectables Spread
1 articles · Updated · The New York Times · Aug 17
Summary
Nearly one in five U.S. adults has tried an injectable GLP-1 drug, underscoring how self-administered shots have moved from diabetes care into mainstream wellness, fertility and cosmetic routines.
That shift is being driven by booming demand for peptides and other injectable supplements, wider use of at-home IVF medications, and Botox's reach — almost 10 million patients received a cosmetic injectable in 2024.
IVF cycles in the United States have risen nearly 40% since 2018, and IV hydration bars have expanded from a niche hangover remedy into hundreds of infusion clinics nationwide.
New York City's sanitation department is seeing a visible side effect: 46 needle-stick injuries from trash collection last year, nearly double 2019, with the first six months of 2026 already close to that total.